Oncodesign Precision Medicine and Navigo Proteins GmbH Sign a Strategic Collaboration Agreement for the Research and Development of New Systemic Radiotherapy Agents
Business Wire
DIJON, France--(BUSINESS WIRE)--Regulatory News: Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a..